Happy Birthday RAI!

March 31, 2018

Happy Birthday RAI!

On this day in 1941, Dr. Saul Hertz administered the very first radioactive iodine therapy to a patient with Graves' Disease. This pivotal treatment was the index case for what we today know as radioactive iodine therapy for hyperthyroidism, and it validated the concept that is now known as theranostics. Seventy-seven years later, we are on the cusp of the next big explosion in the use of therapeutic radiopharmaceuticals in the United States, with SNMMI members at the forefront of these developments.

Help us celebrate these developments, and learn about the current state of theranostics, at SNMMI’s Annual Meeting in June. The 2018 Saul Hertz, MD, Award winner, Dr. Richard Wahl, will be speaking at the Saul Hertz Award Symposium on “Emerging Theranostic Targets,” Monday, June 25, at 12:30 pm. The award recognizes individuals who have made outstanding contributions to radionuclide therapy.

For a deeper dive into the state of theranostics, we encourage you to also attend these pre-meeting categoricals taking place Saturday, June 23:

(CAT1) Radioiodine Theragnostics: Continuing the Update of the Controversies of the Management of Differentiated Thyroid Cancer

I-131 therapy is used more often than all other nuclear medicine therapies combined. The ATA (American Thyroid Association) 2015 guidelines has 34 recommendations that affect the practice of nuclear medicine involving the imaging and therapy of thyroid nodules and differentiated thyroid cancer.

(CAT3) PSMA Radioligand Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by PSMA PET/CT. The Power of Precision Oncology

In this categorical seminar, participants will assess the current state-of-the-art options for therapy of end-stage prostate cancer. This seminar will explore a broad spectrum of the use of PSMA ligands for therapy of prostate cancer, including radiochemical aspects, preclinical studies, the role of PSMA PET/CT (using Ga-68 and F-18) clinical utility, and the state-of-the-art role including newer radionuclides and alpha-targeted radioligand therapy.

These categoricals are sponsored by the SNMMI Therapy Center of Excellence, and Center members can save $20 on their categorical registration. If you are interested in advancing the utilization of radionuclide therapy, we invite you to get involved with SNMMI’s Therapy Center of Excellence!